NervGen Pharma Statistics

Total Valuation

NervGen Pharma has a market cap or net worth of $198.60 million. The enterprise value is $186.74 million.

Market Cap	198.60M
Enterprise Value	186.74M

Important Dates

The next estimated earnings date is Friday, August 14, 2026.

Earnings Date	Aug 14, 2026
Ex-Dividend Date	n/a

Share Statistics

NervGen Pharma has 106.20 million shares outstanding. The number of shares has increased by 6.72% in one year.

Current Share Class	106.20M
Shares Outstanding	106.20M
Shares Change (YoY)	+6.72%
Shares Change (QoQ)	+10.00%
Owned by Insiders (%)	1.91%
Owned by Institutions (%)	4.26%
Float	94.17M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	38.15
P/TBV Ratio	53.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.34

Current Ratio	1.34
Quick Ratio	1.09
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -1,207.46% and return on invested capital (ROIC) is -473.69%.

Return on Equity (ROE)	-1,207.46%
Return on Assets (ROA)	-90.75%
Return on Invested Capital (ROIC)	-473.69%
Return on Capital Employed (ROCE)	-479.57%
Weighted Average Cost of Capital (WACC)	8.05%
Revenue Per Employee	n/a
Profits Per Employee	-$3.00M
Employee Count	10
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -31.00% in the last 52 weeks. The beta is 0.69, so NervGen Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.69
52-Week Price Change	-31.00%
50-Day Moving Average	2.93
200-Day Moving Average	3.58
Relative Strength Index (RSI)	34.05
Average Volume (20 Days)	910,819

Short Selling Information

The latest short interest is 3.45 million, so 3.25% of the outstanding shares have been sold short.

Short Interest	3.45M
Short Previous Month	3.09M
Short % of Shares Out	3.25%
Short % of Float	3.67%
Short Ratio (days to cover)	2.20

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-19.04M
Pretax Income	-29.98M
Net Income	-29.98M
EBITDA	-19.00M
EBIT	-19.04M
Earnings Per Share (EPS)	-$0.45

Full Income Statement

Balance Sheet

The company has $11.86 million in cash and n/a in debt, giving a net cash position of $11.86 million or $0.11 per share.

Cash & Cash Equivalents	11.86M
Total Debt	n/a
Net Cash	11.86M
Net Cash Per Share	$0.11
Equity (Book Value)	3.97M
Book Value Per Share	0.05
Working Capital	3.69M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-16.89M
Capital Expenditures	n/a
Depreciation & Amortization	39,307
Net Borrowing	-59,252
Free Cash Flow	-16.61M
FCF Per Share	-$0.16

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NervGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.72%
Shareholder Yield	-6.72%
Earnings Yield	-15.09%
FCF Yield	-8.36%

Analyst Forecast

The average price target for NervGen Pharma is $11.21, which is 499.47% higher than the current price. The consensus rating is "Buy".

Price Target	$11.21
Price Target Difference	499.47%
Analyst Consensus	Buy
Analyst Count	7
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2